C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Grail, Inc. (NASDAQ:GRAL – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 14,939 shares of the company’s stock, valued at approximately $244,000.
Several other institutional investors have also modified their holdings of GRAL. abrdn plc acquired a new stake in Grail in the 4th quarter valued at about $3,768,000. Douglas Lane & Associates LLC purchased a new stake in shares of Grail in the fourth quarter valued at $3,034,000. Slow Capital Inc. acquired a new stake in shares of Grail during the fourth quarter valued at $2,379,000. 180 Wealth Advisors LLC purchased a new stake in Grail during the 4th quarter worth about $1,681,000. Finally, Moloney Securities Asset Management LLC acquired a new position in Grail in the 4th quarter valued at about $559,000.
Insiders Place Their Bets
In related news, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now owns 268,277 shares of the company’s stock, valued at $3,761,243.54. The trade was a 10.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Grail Trading Up 33.9 %
Grail (NASDAQ:GRAL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($3.94) earnings per share for the quarter. The business had revenue of $28.65 million for the quarter. On average, research analysts predict that Grail, Inc. will post -65.16 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on GRAL shares. Guggenheim started coverage on shares of Grail in a research note on Thursday, October 17th. They set a “neutral” rating on the stock. Wolfe Research assumed coverage on Grail in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Morgan Stanley started coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective for the company.
Get Our Latest Research Report on Grail
Grail Profile
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Articles
- Five stocks we like better than Grail
- About the Markup Calculator
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Insider Buying Explained: What Investors Need to Know
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Stock Average Calculator
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRAL – Free Report).
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.